SCHEDULE: Franklin Resources Amends Benitec Biopharma Stake
Ownership Disclosure
Franklin Resources, Inc. and its affiliates updated their beneficial ownership in Benitec Biopharma Inc. to 14.9% of common stock.
Summary
- Franklin Resources, Inc. and Franklin Advisers, Inc. beneficially own 4,144,037 shares of Benitec Biopharma Inc. common stock.
- This represents 14.9% of the total class of securities.
- The reported amount includes 1,554,404 shares of common stock issuable upon the exercise of warrants.
- Franklin Advisers, Inc. holds sole voting and dispositive power over these 4,144,037 shares.
- Two specific funds managed by Franklin affiliates hold significant interests: Franklin Biotechnology Discovery Fund (U.S.) with 1,441,568 shares (5.2%) and Franklin Biotechnology Discovery Fund (Luxembourg) with 2,702,396 shares (9.72%).
- The filing is an Amendment No. 6 to a Schedule 13G, indicating an update to previously reported ownership.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual ownership disclosure without explicit positive or negative operational or financial news.
Positives
- A major institutional investor, Franklin Resources, maintains a significant stake (14.9%) in Benitec Biopharma, indicating continued investment interest.
- The ownership is stated to be held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer, suggesting a passive investment strategy.
Risks
- No specific risks related to Benitec Biopharma's operations or financial health are disclosed in this ownership filing.
Future Outlook
NA
Industry Context
This filing reflects an institutional investor's continued significant position in a biotechnology company. Such disclosures are standard for large asset managers holding substantial stakes in public companies, particularly in sectors like biopharma where investment can be long-term and strategic.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Disclosure | The filing itself is a corporate governance requirement, ensuring transparency of significant ownership stakes by institutional investors. | 2025-09-30 | Enhances transparency for shareholders and the market regarding the beneficial ownership structure of Benitec Biopharma Inc. |
| Reporting Structure Clarification | The filing clarifies the reporting structure for beneficial ownership within Franklin Resources, Inc. and its subsidiaries, including the use of informational barriers between aggregated and disaggregated affiliates. | NA | Provides clarity on how voting and investment powers are exercised and reported by different entities within the Franklin Resources group. |
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and liquidity.
- Management: Awareness of a large, passive institutional holder and its investment intent.
Key Dates
| Date | Description |
|---|---|
| 2015-10-13 | Date of Limited Power of Attorney for Franklin Templeton Investment Funds. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-10-30 | Date of signing of the Schedule 13G Amendment No. 6. |
Keywords
Benitec Biopharma, Franklin Resources, Franklin Advisers, Schedule 13G, Beneficial Ownership, Institutional Investor, Biopharma, Common Stock, Warrants, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.